CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,234 enrolled
Drug / intervention
Metformin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00004992
NCT00004992Phase 3Completed

Diabetes Prevention Program

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Mar 20, 2000·Updated Mar 2, 2018

In Brief

A Phase 3 clinical trial evaluating Intensive lifestyle, Metformin, and 1 other intervention for Diabetes Mellitus, Non-Insulin-Dependent and Glucose Intolerance. Completed, enrolled 3,234 participants across 1 site.

Detailed Summary

The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.

Study Details

Timeline

Phase 3CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 20, 2000
Enrollment StartJul 1, 1996
Primary CompletionApr 1, 2001
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 26.3 years ago

Interventions

Intensive lifestylebehavioral

Metformindrug

Placebodrug